Insilico Medicine, an end-to-end AI-powered drug discovery company, has announced the appointment of Robert Spiegel as acting CMO to oversee the clinical translation of its preclinical pipeline assets. Dr. Spiegel brings over 35 years of extensive R&D executive and operational experience in biopharmaceuticals and as an advisor to venture capital and private equity firms. “It…